And you improve your metabolic health
In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norwayinvolving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [12]
382 Potential targets include PPAR, Apoliprotein E (ApoE), Apolipoprotein E receptor (LRP1), and leptin
GLP-1 stimulates the release of insulin in the pancreas after eating, especially when blood sugar is elevated
Khwaja A
No, Combining two GLP-1 class compounds would not be appropriate in any clinical or research context and could cause significant adverse effects